Summit Therapeutics (NASDAQ:SMMT – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at HC ...

Summit Therapeutics, Inc. shares rebounded in after-hours trading on Monday after a 14% selloff during regular hours, with ...

We recently published a list of 10 Stocks Drop The Most Amid Investor Caution. In this article, we are going to take a look ...

Pfizer has teamed up with Summit Therapeutics to assess whether one of the industry’s hottest cancer candidates works well ...

Summit Therapeutics established a clinical trial collaboration with Pfizer to develop ivonescimab for NSCLC and solid tumors.

Q4 2024 Earnings Call Transcript February 24, 2025 Operator: Good morning and welcome to Summit Therapeutics Fourth Quarter and Year End 2024 Earnings and Update Call. All participants will be in ...

Summit Therapeutics shares are dropping Monday morning as it reported a fourth-quarter adjusted loss nearly double that of ...

The partners will test Summit’s ivonescimab alongside Pfizer’s antibody-drug conjugates in hopes of finding “potentially ...

Summit Therapeutics (SMMT) announced a clinical trial collaboration with Pfizer (PFE) to evaluate ivonescimab, an investigational PD-1 / VEGF ...

Pfizer partners with Summit Therapeutics to advance cancer treatments using ADCs and ivonescimab. Click here to find out why ...

We recently published a list of 12 Best Growth Stocks to Invest In According to Analysts. In this article, we are going to ...

Plasma p-tau217 can be measured using a simple blood test, providing patients and their physicians with an important tool they can use to tailor their personalized treatment regimens.” The Hanson Wade ...